索拉非尼治疗肝移植后肝细胞癌复发的单中心回顾性分析

Single center retrospective analysis of sorafenib in the treatment of hepatocellular carcinoma recurrence after liver transplantation

目的:通过收集分析单中心索拉非尼治疗肝移植后肝细胞癌复发人群数据,探讨索拉非尼在肝细胞癌肝移植患者中的应用。方法:收集2011—2016年在天津市第一中心医院肝移植术后肝细胞癌复发使用索拉非尼和最佳支持治疗(BSC)的患者资料41例。索拉非尼组27例,BSC组14例。比较两组的生存时间差异,并探讨索拉非尼的安全性。结果:索拉非尼组复发后生存时间为4~48个月,中位生存时间11个月;BSC组生存时间1~24个月,中位生存时间4个月,两组中位生存时间差异具有统计学意义(P<0.01)。27例服药患者资料中,不良事件发生率不高,3级以上1例,该患者严重腹泻,予停药。结论:服用索拉非尼整体生存率较BSC高,部分患者用药后可出现轻微不良事件。索拉非尼可以较好改善肝移植后肝细胞癌复发患者预后。

Objective:To investigate the application of sorafenib in patients with hepatocellular carcinoma liver transplantation by collecting and analyzing the single-center data of sorafenib in the treatment of hepatocellular carcinoma recurrence after liver transplantation.Methods:The data of 41 patients who used sorafenib and best supportive care(BSC)for hepatocellular carcinoma recurrence after liver transplantation in Tianjin First Central Hospital from 2011 to 2016 were collected.The patients were divided into sorafenib group(27 cases)and BSC group(14 cases).The difference in survival time was compared and the safety of sorafenib was discussed.Results:The survival time was 4-48 months and the median survival time after recurrence was 11 months in the sorafenib group;the survival time was 1-24 months and the median survival time after recurrence was 4 months in the BSC group.There was a statistically significant difference in median survival time between the two groups(P<0.01).In the data of 27 patients taking medication,the incidence of adverse events(AEs)was not high.One patient with grade 3 or above had severe diarrhea and was stopped medication.Conclusion:The overall survival rate of patients taking sorafenib is higher than that of the BSC group,and some patients may have mild adverse events after taking the drug.Sorafenib can better improve the prognosis of patients with hepatocellular carcinoma recurrence after liver transplantation.